Biotech Faces a Real Estate Shortage
In this episode of TechTalk, we learn about the real estate shortage in the nation’s biotech hubs, the challenges of obtaining and creating new space, how early-stage companies are coping, and what’s on the drawing board to help alleviate the shortage.
Dave Plaskow: Hello, and welcome to EisnerAmper’s technology podcast series. With more than 500 hundred technology clients, we’re always interested in the latest industry trends and developments, as well as any related business and accounting opportunities and challenges. This time, we’re turning our attention to the biotech sector, specifically, the challenge of biotechs finding available real estate. I’m your host, Dave Plaskow, and with us today is Dave Katz, Senior Manager in EisnerAmper’s Technology and Life Sciences Practice. We like to call this the Dave & Dave show. Dave, welcome, and thanks for being here.
Dave Katz: Thanks Dave.
DP: So Dave, give us the lay of the land, so to speak, when it comes to biotech real estate.
DK: Well, there’s good news and there’s bad news. Good news is there’s never been a better time to be in the biotech sector, but the bad news is there’s simply not enough workspace to meet the demand. If you look at the biotech hubs such as San Francisco, Boston, New York, you’ll find extremely limited vacancies – somewhere in the 1% to 3% – sky-high prices, design issues for expanding or creating a biotech structure. That makes it challenging for larger firms to secure space and nearly impossible for startups to put a roof over their heads.
DP: What kind of sky-high prices are we talking about?
DK: If you look Cambridge, just over the river from Boston, rents are in the $70 to $80 per square foot range and increasing at a rate of 10% to 15% annually. Prices for Kendall Square’s Lab Central incubator, which is in the heart of Boston’s biotech sector, start at $400 per month for membership, $3,800 per month for a bench spot, and $430 to $535 per month for a lab desk. Private suites costs $16,000 to $18,000 per month, and additional office space is somewhere in the $1000 to $3000 per month range, and that’s a lot of money and tall prices for early bio stage companies.
DP:So instead of renting, why not just build more incubators or maybe look at some commercial real estate and just retrofit that?
DK: Yes, it’s a good question. So, biotech has very specific requirements as to water systems, fire suppression systems, HVAC, electrical systems. In addition, the local permit process can be lengthy and expensive. That’s why improvements cost in the $200 per square foot range, and new construction could be upwards of $600 per square foot.
DP:The numbers are pretty daunting. So what does that mean for the small, early stage startups?
DK: Many are fleeing to the suburbs. You go to Boston, they’re going to Watertown; you go to San Fran, they’re going to the Peninsula or East Bay or Marin County; New York to Westchester or to New Jersey; and in these suburbs, commercial real estate is plentiful post-great recession, costs are significantly less. There’s also biotech space available at former pharma locations like Roche in northern New Jersey. So small companies are increasingly using virtual biotech, being based in an urban hub but outsourcing the lab work to research organizations located elsewhere.
DP:That all sounds good, but I’m assuming that nothing beats being centrally located in a big city.
DK: That’s right. There’s really no substitute for being in a downtown life science community with easy access to funding, service providers, research institutions, hospitals, universities and a broadly talented work base, and politicians in these cities are also starting to gain a better understanding of the value of becoming a biotech hub.
DP: Any major construction on the drawing board?
DK: Officials in New York are interested in putting life science facilities on Roosevelt Island and near Bellevue Hospital. A relatively new incubator, Harlem Biospace, offers workspace to early stage companies for about $1,000 per month, and the Alexandria Center is undergoing significant expansion with its LaunchLabs to help offer affordable space for seed-stage companies with rents in the $2,000 per month. LaunchLabs hopes to open in 2017. And then you have BioBAT at the Brooklyn Army Terminal, which offers 500,000 square feet of space. So, thus far, most takers have been mature and mid-stage companies, but we might see some early stage companies get in there as well. In San Fran, the Cove at Oyster Point will bring an additional 1 million square feet of biospace to the city when complete in 2017. Also, Genesis Towers in South San Fran will add more than 800,000 square feet by early 2018. We may also see the continued development of up-and-coming biotech hubs like Seattle and Texas, so these developments are encouraging.
DP:You’re a business advisor, you’re out at clients, on the frontlines so to speak. Where do you fit into all this? Where can you help these companies that are looking to efficiently and price-effectively obtain real estate?
DK: So there’s ample opportunities, whether it’s performing cost segregation studies, due diligence, calculating NOLs or forensic accounting. We can help mitigate some of the sticker shock for life science companies looking to expand or acquire space.
DP:Well Dave, thanks as always for your expertise and your insight.
DK: Thanks Dave.
DP:And thank you for listening to the Dave & Dave Show, as part of the EisnerAmper podcast series. Visit EisnerAmper.com for more information on this, and a host of other topics, and join us for our next EisnerAmper podcast when we get down to business.
EisnerAmper’s Technology and Life Sciences practice talks about the Theranos dissolution, and what took them from biotech unicorn to dissolution. Investors must use due diligence and consider a company's internal controls before investing in companies with high valuations.
EisnerAmper's Technology podcast series discusses the proposed New York City Council cap on the number of ridesharing vehicles such as Lyft and Uber in Manhattan to ease congestion. How will this cap change Uber's valuation, and what is the economic hit to the taxi industry?
This episode of the Dave & Dave Show discusses new cryptocurrency technology from the fintech startup company Circle, called USD Coin. This cryptocurrency ties itself to the U.S. Dollar, therefore eliminates some volatility that comes with crypto mining and Bitcoin.
TechTalk takes a look at a tech startup, Aerobotics, that is using drones to help farmers in South Africa. This podcast discusses how the drones help South African farmers, how the US government is using drones and how MIT is making micro drones.
TechTalk discusses a new 3d printed community proposed in El Salvador by the nonprofit New Story and ICON construction. Icon and New Story debuted their 3D printed house at the Austin South by Southwest festival. Issues discussed include cybersecurity and valuation.
Life Science Partner Dave Katz discusses the new 23andMe DNA testing kit for breast cancer BRCA1 and BRCA2 gene mutations approved by the FDA, and what it means for the biotech industry. The FDA approved 23andMe DNA breast cancer test increases access to health care information.
TechTalk examines Jeff Bezos' new possible Amazon facility cities of Austin, New York City, Washington DC and Atlanta, with Atlanta being Dave Katz' first pick. They also discuss Amazon Go, and Amazon's healthcare initiative with Berkshire Hathaway.
EisnerAmper’s technology podcast discusses the first FDA approved EKG band for the Apple Watch. Dave Katz of the Technology and Life Sciences practice discuses these new medical devices, their use of artificial intelligence and the cybersecurity issues surrounding them.
EisnerAmper’s technology podcast discusses related business and accounting opportunities with the senior manager in its Technology and Life Sciences practice about Uber, drones, internet providers and net neutrality, IPOs, AI and the R&D credit that may expire next year.
Is AI Destined to Replace Fund Managers? This episode of TechTalk talks about the first ETF powered by artificial intelligence (AI), the technology behind it, if it impacts a fund’s expense ratio and, most importantly, how it’s performing.
It was a milestone when Facebook implemented facial recognition software in 2010. The iPhone X has put a renewed spotlight on facial recognition technology. EisnerAmper’s Technology and Life Sciences Manager discusses security issues surrounding facial recognition technology.
Supersonic air travel is coming back with a boom. What does today’s market look like for supersonic air travel and how are start-ups such as Boom and Aerion navigating the many challenges? Also discussed is mergers and acquisitions and the need for valuations.
Is iRobot’s Roomba automated vacuum collecting consumer data that will be offered to technology companies to enhance internet of things devices? Here is what information is being collected, potential data privacy and security issues, and iRobot’s response to consumer concerns.
Tesla has received a significant investment from Chinese tech giant Tencent. This podcast discusses what Tesla plans to do with the cash infusion, Tencent’s ownership stake and how this could help both companies enter the highly coveted self-driving car market.
Amazon’s CEO Jeff Bazos just passed Warren Buffet to become the second wealthiest person on the planet. In Technology M&A news, Amazon competes with Alibaba by buying Dubai based Souq in a battle over E-commerce in the middle east, as reported by EisnerAmper’s Life Sciences Practice.
With retiring baby boomers some of the fastest growing jobs in technology attracting tech talent are located in New York City, San Francisco, Austin and Seattle. Tech talent can come from non-traditional backgrounds and there is strong hiring growth in hubs such as New York City.
Amazon Go wants to streamline your grocery shopping. This podcast discusses Amazon’s plan to use 'Just Walk Out Technology' to change food shopping. A look at the technology behind Amazon Go, potential speedbumps and what it could mean for bricks-and-mortar grocery chains.
David in EisnerAmper’s Technology and Life Sciences Practice, gives a “state of the union” on self-driving cars, an overview of Uber’s unique experiment in Pittsburgh, and a glimpse of what we can expect in the marketplace over the next few years.
This Life Sciences and Technology podcast talks about the space-age technology called the Hyperloop. The Hyperloop could take people from LA to San Francisco in 35 minutes, and was originally conceived by Elon Musk. Hyperloop One is the first company to develop the technology.
David discusses the commercial drone market, including how the FAA will regulate pilot licenses, drone use in real estate, Amazon's use of drones for future deliveries, the VC market and M&A strategies for companies interested in investing in drone technology.
David discusses virtual reality including Facebook's acquisition of Oculus, HTC's Vive and revenue recognition that comes from virtual reality technology. HTC has created the Vive X Fund and Facebook has created a similar fund to help develop virtual reality software.